Skip to main content
. Author manuscript; available in PMC: 2014 May 9.
Published in final edited form as: Cancer. 2011 Sep 1;118(9):2507–2515. doi: 10.1002/cncr.26517

Table 1.

Treatment Schema

Group1 Group2 Group3
Melphalan 100 mg/m2 IV
Days −4, −3
100 mg/m2 IV
Days −4, −3
100 mg/m2 IV
Days −4, −3
Ascorbic Acid 1000 mg IV
Days −9 to −3
1000 mg IV
Days −9 to −3
1000 mg IV
Days −9 to −3
Arsenic Trioxide 0.25 mg/kg
Days −9 to −3
0.25 mg/kg
Days −9 to −3
0.25 mg/kg
Days −9 to −3
Bortezomib None 1 mg/m2
Days −9, −6, −3
1.5 mg/m2
Days −9, −6, −3
HHS Vulnerability Disclosure